KEY TAKEAWAYS
- The study aimed to identify an association between LIPI and the survival post-ICI treatment of pts with NSCLC.
- The results showed that the higher LIPI predicts worse survival in pts with NSCLC treated with ICIs.
Predicting the efficacy of immunotherapy in patients (pts) with non-small cell lung cancer (NSCLC) has posed significant challenges. However, a novel indicator, the Lung Immune Prognostic Index (LIPI), has demonstrated notable prognostic value in patients with solid tumors, including NSCLC.
Yi Wang and the team aimed to identify an association between LIPI and the survival of pts with NSCLC previously receiving immune checkpoint inhibitors (ICIs).
Several electronic databases have been searched to obtain the available publications up to April 23, 2023. Immunotherapy outcomes included overall survival (OS), progression-free survival (PFS), and hazard ratios (HRs) with 95% confidence intervals (CIs). A subgroup analysis was conducted based on the study design, and a comparison of the LIPI was conducted.
About 21 studies, including 9,010 pts, were performed in this meta-analysis. The comprehensive analysis revealed that an elevated LIPI was significantly linked to poorer OS, with an HR of 2.50 (95% CI: 2.09-2.99, P< 0.001). Similarly, PFS was adversely affected by elevated LIPI, indicated by an HR of 1.77 (95% CI: 1.64-1.91, P< 0.001).
The subgroup analysis was conducted to determine the differentiation outcome based on study design, comparing retrospective vs. prospective studies. The comparative analysis of LIPI levels (1 vs. 0, 2 vs. 0, 1-2 vs. 0, 2 vs. 1 vs. 0, 2 vs. 0-1, and 2 vs. 1) persistently reflected similar findings.
These analyses further confirmed the finding that higher LIPI has a statistically significant association with poorer survival outcomes in patients with NSCLC who were receiving ICIs as treatment.
The study projected LIPI as a potentially novel and reliable prognostic parameter for pts with NSCLC and those treated with ICIs. Elevated LIPI was found to predict a poor prognosis, advocating its prospective clinical implication in the assessment and planning the treatment strategies for pts with NSCLC undergoing ICI-based treatment.
No financial support was received for the research, authorship, and/or publication of this article.
Source: https://pubmed.ncbi.nlm.nih.gov/38966280/
Wang Y, Lei Y, Zheng D, et al. (2024). “Prognostic value of lung immune prognostic index in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a meta-analysis.” Pathol Oncol Res. 2024 Jun 20;30:1611773. doi: 10.3389/pore.2024.1611773. PMID: 38966280; PMCID: PMC11222319.
